Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness

Tabled by Viktória Ferenc, Kinga Gál, Enikő Győri, András Gyürk, György Hölvényi, András László, Pál Szekeres, Annamária Vicsek, Jorge Buxadé Villalba, Hermann Tertsch, Juan Carlos Girauta Vidal, Mireia Borrás Pabón, Margarita de la Pisa Carrión, Jorge Martín Frías, Afroditi Latinopoulou, Rachel Blom, Ton Diepeveen, Marieke Ehlers, Sebastian Kruis, Sebastiaan Stöteler, Auke Zijlstra, Elisabeth Dieringer, Gerald Hauser, Petra Steger, Harald Vilimsky, Georg Mayer, Roman Haider, Filip Turek, Jaroslav Bžoch, Klara Dostalova, Ondřej Knotek, Tomáš Kubín, Jana Nagyová, Jaroslava Pokorná Jermanová, Nikola Bartůšek, Anders Vistisen, Mathilde Androuët, Jordan Bardella, Christophe Bay, Marie-Luce Brasier-Clain, Marie Dauchy, Valérie Deloge, Mélanie Disdier, Anne-Sophie Frigout, Angéline Furet, Jean-Paul Garraud, Catherine Griset, France Jamet, Virginie Joron, Fabrice Leggeri, Thierry Mariani, Aleksandar Nikolic, Philippe Olivier, Gilles Pennelle, Pascale Piera, Pierre Pimpie, Julie Rechagneux, André Rougé, Julien Sanchez, Pierre-Romain Thionnet, Rody Tolassy, Matthieu Valet, Alexandre Varaut, Séverine Werbrouck, Csaba Dömötör, Ernő Schaller-Baross, Paolo Borchia, Susanna Ceccardi, Anna Maria Cisint, Aldo Patriciello, Silvia Sardone, Raffaele Stancanelli, Isabella Tovaglieri, Roberto Vannacci

Added: Sa. whereas such a framework and the ethical foundation of the EU should be based on core values such as the inviolability of human dignity, the integrity of the person, the primacy of the human being over the sole interests of science or industry, the prohibition of reproductive cloning and eugenic practices, the requirement of free and informed consent for any medical intervention, the prohibition of financial profit from the human body and its parts, the non-patentability of living human matter, and the rejection of discrimination based on genetic characteristics; whereas this must include, among other things, strict compliance with rules on genetically modified organisms (GMOs), the prohibition of certain biotechnological practices deemed incompatible with human dignity and characteristics of human species and sexes, safeguards concerning the prohibition of enhancement of human embryos and germ cells, regulations on the use of stem cells and synthetic gametes, prior authorisation procedures for clinical and medical applications, transparency obligations and requirements for the protection of genetic data; whereas the Member States must retain the right to adopt more restrictive measures in the field of bioethics, without such measures being regarded as obstacles to the functioning of the internal market or to the development of the EU’s industrial strategy;

Wording as published by the EP, in English. PE773.999v01-00